Table 1.

In vitro anti-proliferative activity of the target coumarin sulfonamide derivatives against HepG2, MCF-7 and Caco-2 cancer cell lines.

Compound	IC50 (µM)a
	HepG2	MCF7	Caco-2
4a	35.48 ± 2.93	50.73 ± 4.61	192.69 ± 15.33
4b	8.08 ± 0.51	22.95 ± 2.04	66.88 ± 6.07
6	25.62 ± 1.36	>200	81.54 ± 6.89
8a	26.99 ± 2.01	14.30 ± 1.18	8.53 ± 0.72
8b	11.84 ± 1.34	126.08 ± 10.87	89.59 ± 7.26
8c	29.80 ± 2.21	>200	76.93 ± 6.59
8d	89.91 ± 7.63	>200	16.02 ± 1.32
9	163.03 ± 10.22	>200	>200
11a	>200	13.86 ± 1.19	10.12 ± 0.90
11b	54.31 ± 3.87	63.42 ± 5.69	145.46 ± 8.02
11c	72.50 ± 6.33	34.73 ± 2.94	108.41 ± 11.36
11d	>200	>200	16.06 ± 1.28
13a	3.48 ± 0.28	83.23 ± 6.85	83.43 ± 7.04
13b	11.80 ± 1.16	>200	96.64 ± 5.37
15a	5.03 ± 0.39	10.95 ± 0.96	158.38 ± 9.39
15b	25.07 ± 2.08	10.62 ± 1.35	174.91 ± 12.30
15c	7.57 ± 0.66	16.32 ± 1.48	46.06 ± 3.17
Doxorubicin	5.43 ± 0.24	3.18 ± 0.32	4.10 ± 1.37

^aIC₅₀ values are the mean ± SE of three separate experiments.